


 **Sterne Kessler  
Goldstein Fox**  
ATTORNEYS AT LAW



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugaisky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Heidi L. Kraus  
Edward W. Yee  
Albert L. Ferro\*  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Eldora Ellison Floyd  
Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beaston  
Kimberly N. Reddick

Theodore A. Wood  
Elizabeth J. Haanes  
Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Lhulier  
Rae Lynn Pngaman  
Jane Shershenovich\*  
Lawrence J. Carroll\*  
George S. Bardmesser  
Daniel A. Klein\*  
Jason D. Eisenberg  
Michael D. Specht  
Andrea J. Kamage  
Tracy L. Muller  
LuAnne M. Yuricek\*  
John J. Figueroa  
Ann E. Summerfield  
Tiera S. Coston\*

Aric W. Ledford\*  
**Registered Patent Agents\***  
Karen R. Markowicz  
Nancy J. Leith  
Helene C. Carlson  
Gaby L. Longworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Mary B. Tung  
Katrina Y. Pei Quach  
Bryan L. Skelton  
Robert A. Schwartzman  
Timothy A. Doyle  
Jennifer R. Mahalingappa  
Teresa A. Colella  
Jeffrey S. Lundgren

Victoria S. Rutherford  
Eric D. Hayes

**Of Counsel**  
Kenneth C. Bass III  
Evan R. Smith

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice Limited to  
Federal Agencies

February 25, 2004

**WRITER'S DIRECT NUMBER:**  
(202) 772-8637  
**INTERNET ADDRESS:**  
KAREN@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Re: U.S. Utility Patent Application  
Application No. 10/721,336; Filed: November 26, 2003  
For: **Connective Tissue Growth Factor-3**  
Inventors: Ebner *et al.*  
Our Ref: 1488.0630003/EKS/KRM

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. Listing of the cited documents on Form PTO-1449 (13 sheets);
3. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
4. Listing of the cited document on Form PTO-1449 (1 sheet);
5. Second Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
6. Listing of the cited documents on Form PTO-1449 (1 sheet);
7. Third Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
8. Listing of the cited documents on Form PTO-1449 (2 sheets);
9. Fourth Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);

Commissioner for Patents  
February 25, 2004  
Page 2


10. Listing of the cited documents on Form PTO-1449 (3 sheets); and
11. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz  
Agent for Applicants  
Registration No. 36,351

KRM/pcd  
Encls.

234214v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Ebner *et al.*

Appl. No. 10/721,336

Filed: November 26, 2003

For: **Connective Tissue Growth  
Factor - 3**

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 1488.0630003/EKS/KRM

**Information Disclosure Statement  
Under 37 C.F.R. § 1.97(b)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of the documents were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/712,142, filed November 15, 2000, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.


Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed within three months of the date of filing. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz  
Agent for Applicants  
Registration No. 36,351

Date: 2/25/04

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1488.0630003/EKS/KRMAPPLICATION NO.  
10/721,336APPLICANT  
Ebner et al.FILING DATE  
November 26, 2003GROUP  
To Be Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	5,408,040	04/18/1995	Grotendorst et al.	530	399	12/14/1993
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	EP 0 495 674 A2	07/22/1992	Europe			Yes No
	AM1	WO 96/01896	01/25/1996	WIPO			Yes No
	AN1	WO 98/58063	12/23/1998	WIPO			Yes No
	AO1	WO 99/14327	03/25/1999	WIPO			Yes No
	AP1	WO 99/21998	05/06/1999	WIPO			Yes No


## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>1</u>	Barton, G.J., "Protein sequence alignment and database scanning," in <i>Protein Structure Predication, A Practical Approach</i> , IRL Press at Oxford University Press, Oxford, UK, pp. 31-63 (1996).
	AS	<u>1</u>	Bork, P., "The modular architecture of a new family of growth regulators related to connective tissue growth factor," <i>FEBS Lett.</i> 327:125-130, Elsevier Science Publishers B.V. (1993).
	AT	<u>1</u>	Bowie, J.U. et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> 247:1306-1310, American Association for the Advancement of Science (1990).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1488.0630003/EKS/KRM

APPLICATION NO.  
10/721,336

APPLICANT  
Ebner et al.

FILING DATE  
November 26, 2003

GROUP  
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


	AR	2	Bradham, D.M. et al., "Connective Tissue Growth Factor: a Cystein-rich Mitogen Secreted by Human Vascular Endothelial Cells Is Related to the SRC-induced Immediate Early Gene Product CEF-10," <i>J. Cell Biol.</i> 114:1285-1294, Rockefeller University Press (1991).
	AS	2	Daniel, C. et al., "Mapping of Linear Antigenic Sites on the S Glycoprotein of a Neurotropic Murine Coronavirus with Synthetic Peptides: A Combination of Nine Prediction Algorithms Fails To Identify Relevant Epitopes and Peptide Immunogenicity Is Drastically Influenced by the Nature of the Protein Carrier," <i>Virology</i> 202:540-549, Academic Press, Inc. (1994).
	AT	2	DiCorleto, P.E., "Cultured Endothelial Cells Produce Multiple Growth Factors for Connective Tissue Cells," <i>Exp. Cell Res.</i> 153:167-172, Academic Press, Inc. (1984).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.0630003/EKS/KRM	APPLICATION NO. 10/721,336
APPLICANT Ebner et al.		
FILING DATE November 26, 2003		GROUP To Be Assigned




U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>3</u>	George, D.G. et al., "Current Methods in Sequence Comparison and Analysis," in <i>Macromolecular Sequencing and Synthesis, Selected Methods and Applications</i> , D.H. Schlesinger (ed.), Alan R. Liss, Inc., New York, NY, pp.127-149 (1988).
	AS	<u>3</u>	Grotendorst, G.R., "Connective Tissue Growth Factor: a Mediator of TGF-β Action on Fibroblasts," <i>Cytokine &amp; Growth Factor Reviews</i> 8:171-179, Elsevier Science Ltd. (September, 1997).
	AT	<u>3</u>	Henikoff, S. et al., "Gene Families: The Taxonomy of Protein Paralogs and Chimeras," <i>Science</i> 278:609-614, American Association for the Advancement of Science (October, 1997).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1488.0630003/EKS/KRM

APPLICATION NO.  
10/721,336

APPLICANT  
Ebner et al.

FILING DATE  
November 26, 2003

GROUP  
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


	AR	<u>4</u>	Igarashi, A. et al., "Connective Tissue Growth Factor," <i>J. Dermatol.</i> 19:642-643, Blackwell Science Ltd. (1992).
	AS	<u>4</u>	Igarashi, A. et al., "Significant Correlation Between Connective Tissue Growth Factor Gene Expression and Skin Sclerosis in Tissue Sections from Patients with Systemic Sclerosis," <i>J. Invest. Dermatol.</i> 105:280-284, The Society for Investigative Dermatology, Inc. (August, 1995).
	AT	<u>4</u>	Igarashi, A. et al., "Connective Tissue Growth Factor Gene Expression in Tissue Sections From Localized Scleroderma, Keloid, and Other Fibrotic Skin Disorders," <i>J. Invest. Dermatol.</i> 106:729-733, The Society for Investigative Dermatology, Inc. (April, 1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.





FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1488.0630003/EKS/KRM

APPLICATION NO.  
10/721,336

APPLICANT  
Ebner et al.

FILING DATE  
November 26, 2003

GROUP  
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Jalkanen, M. et al., "Heparan Sulfate Proteoglycans from Mouse Mammary Epithelial Cells: Localization on the Cell Surface with a Monoclonal Antibody," <i>J. Cell Biol.</i> 101:976-984, The Rockefeller University Press (1985).
	AS	<u>5</u>	Jalkanen, M. et al., "Cell Surface Proteoglycans of Mouse Mammary Epithelial Cells Is Shed by Cleavage of Its Matrix-binding Ectodomain from Its Membrane-associated Domain," <i>J. Cell Biol.</i> 105:3087-3096, The Rockefeller University Press (1987).
	AT	<u>5</u>	Kumar, S. et al., "Identification and Cloning of a Connective Tissue Growth Factor-like cDNA from Human Osteoblasts Encoding a Novel Regulator of Osteoblast Functions," <i>J. Biol. Chem.</i> 274:17123-17131, The American Society for Biochemistry and Molecular Biology, Inc. (June, 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.  
1488.0630003/EKS/KRM

APPLICATION NO.  
10/721,336

INFORMATION DISCLOSURE STATEMENT

APPLICANT  
Ebner et al.

FILING DATE  
November 26, 2003

GROUP  
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	6	Luckow, V.A. and Summers, M.D., "High Level Expression of Nonfused Foreign Genes with <i>Autographa californica</i> Nuclear Polyhedrosis Virus Expression Vectors," <i>Virology</i> 170:31-39, Academic Press, Inc. (1989).				
	AS	6	Mathews, C.K. and van Holde, K.E., <i>Biochemistry, Second Edition</i> , The Benjamin/Cummings Publishing Company, Inc., Menlo Park, CA, pp.142-146 (1996).				
	AT	6	Oemar, B.S., et al., "Human Connective Tissue Growth Factor in Atherosclerosis and Restenosis," <i>Circulation (Suppl. 1)</i> 92:I-170 (Abstract 0811), American Heart Association (October, 1995).				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.0630003/EKS/KRM	APPLICATION NO. 10/721,336
	APPLICANT Ebner et al.	
	FILING DATE November 26, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>7</u>	Pennica, D. et al., "WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1 transformed cells and aberrantly expressed in human colon tumors," <i>Proc. Natl. Acad. Sci. USA</i> 95:14717-14722, The National Academy of Sciences of the USA (December, 1998).
	AS	<u>7</u>	Ryseck, R.-P. et al., "Structure, Mapping, and Expression of <i>fisp-12</i> , a Growth Factor-inducible Gene Encoding a Secreted Cysteine-rich Protein," <i>Cell Growth &amp; Differentiation</i> 2:225-233, American Association for Cancer Research (1991).
	AT	<u>7</u>	Sambrook, J. et al., eds., "Expression of Cloned Genes in Cultured Mammalian Cells," Chapter 16 and Chapter 17, p.17.2 in <i>Molecular Cloning: A Laboratory Manual, Second Edition</i> , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, U.S.A. (1989).

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.0630003/EKS/KRM	APPLICATION NO. 10/721,336
	APPLICANT Ebner <i>et al.</i>	
	FILING DATE November 26, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	<u>8</u>	Smith, D.B. and Johnson, K.S., "Single-step purification of polypeptides expressed in <i>Escherichia coli</i> as fusions with glutathione S-transferase," <i>Gene</i> 67:31-40, Elsevier Science Publishers B.V. (1988).				
	AS	<u>8</u>	Smith, T.F. and Waterman, M.S., "Comparison of Biosequences," <i>Adv. In Appl. Math.</i> 2:482-489, Academic Press, Inc.(1981).				
	AT	<u>8</u>	Xin, L.W. et al., "Differential expression of novH and CTGF in human glioma cell lines," <i>J. Clin. Pathol.: Mol. Pathol.</i> 49:M91-M97, BMJ Publishing Group (April, 1996).				

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.0630003/EKS/KRM	APPLICATION NO. 10/721,336
	APPLICANT Ebner et al.	
	FILING DATE November 26, 2003	GROUP To Be Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>2</u>	NCBI Entrez, GenBank Accession No. C01967, from Okubo, K. (July, 1996).
	AS	<u>2</u>	NCBI Entrez, GenBank Accession No. AA187512, from Hillier, L. et al. (January, 1997).
	AT	<u>2</u>	NCBI Entrez, GenBank Accession No. AA304688, from Adams, M.D. et al. (April, 1997).

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.0630003/EKS/KRM	APPLICATION NO. 10/721,336
	APPLICANT Ebner et al.	
	FILING DATE November 26, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>10</u>	NCBI Entrez, GenBank Accession No. AA318364, from Adams, M.D. et al. (April, 1997).
	AS	<u>10</u>	NCBI Entrez, GenBank Accession No. AA373233, from Adams, M.D. et al. (April, 1997).
	AT	<u>10</u>	NCBI Entrez, GenBank Accession No. AA373257, from Adams, M.D. et al. (April, 1997).

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.0630003/EKS/KRM	APPLICATION NO. 10/721,336
	APPLICANT Ebner <i>et al.</i>	
	FILING DATE November 26, 2003	GROUP <i>To Be Assigned</i>

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>11</u>	NCBI Entrez, GenBank Accession No. AA373788, from Adams, M.D. <i>et al.</i> (April, 1997).
	AS	<u>11</u>	NCBI Entrez, GenBank Accession No. AA374371, from Adams, M.D. <i>et al.</i> (April, 1997).
	AT	<u>11</u>	NCBI Entrez, GenBank Accession No. AA374626, from Adams, M.D. <i>et al.</i> (April, 1997).

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.0630003/EKS/KRM	APPLICATION NO. 10/721,336
	APPLICANT Ebner et al.	
	FILING DATE November 26, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>12</u>	NCBI Entrez, GenBank Accession No. AA377456, from Adams, M.D. et al. (April, 1997).
	AS	<u>12</u>	NCBI Entrez, GenBank Accession No. AA385680, from Adams, M.D. et al. (April, 1997).
	AT	<u>12</u>	NCBI Entrez, GenBank Accession No. AA717584, from Marra, M. et al. (December, 1997).

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 1488.0630003/EKS/KRM	APPLICATION NO. 10/721,336
APPLICANT Ebner et al.		
FILING DATE November 26, 2003	GROUP To Be Assigned	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>13</u>	NCBI Entrez, GenBank Accession No. AA754979, from Marra, M. et al. (January, 1998).
	AS		
	AT		

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Ebner *et al.*

Appl. No. 10/721,336

Filed: November 26, 2003

For: **Connective Tissue Growth  
Factor - 3**

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 1488.0630003/EKS/KRM

**First Supplemental Information Disclosure Statement  
Under 37 C.F.R. § 1.97(b)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed herewith in connection with the above-captioned application. A copy of the document was cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/712,142, filed November 15, 2000, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, a copy of this document is not attached. 37 C.F.R. § 1.98(d).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates

should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed within three months of the date of filing. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz  
Agent for Applicants  
Registration No. 36,351

Date: 2/25/04

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



FORM PTO-1449

FIRST SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1488.0630003/EKS/KRM

APPLICATION NO.  
10/721,336

APPLICANT  
Ebner et al.

FILING DATE  
November 26, 2003

GROUP  
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	WO 96/38168	12/05/1996	WIPO			Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


	AR						
	AS						
	AT						

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Ebner *et al.*

Appl. No. 10/721,336

Filed: November 26, 2003

For: **Connective Tissue Growth  
Factor - 3**

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 1488.0630003/EKS/KRM

**Second Supplemental Information Disclosure Statement  
Under 37 C.F.R. § 1.97(b)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed herewith in connection with the above-captioned application. Copies of the documents were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/712,142, filed November 15, 2000, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to SEQ ID NOS:1762, 73132, and 196475 in copending U.S. Patent Application Serial No. 09/912,293, and to

SEQ ID NO:46156 in copending U.S. Patent Application Serial No. 09/912,292.

Further, SEQ ID NO:10 of this application is related to SEQ ID NO:196475 in copending U.S. Patent Application Serial No. 09/912,293, and SEQ ID NO:11 of this application is related to SEQ ID NO:46156 in copending U.S. Patent Application Serial No.

09/912,292. Legible copies of those portions of U.S. Patent Application Serial Nos.

09/912,292 and 09/912,293 which caused them to be listed on the attached PTO-1449 were submitted previously as references AS13 and AT13, respectively.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed within three months of the date of filing. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz  
Agent for Applicants  
Registration No. 36,351

Date: 2/25/04

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

FORM PTO-1449

SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1488.0630003/EKS/KRMAPPLICATION NO.  
10/721,336APPLICANT  
Ebner et al.FILING DATE  
November 26, 2003GROUP  
To Be Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB1						
	AC1						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR						
	AS	<u>13</u>					Pending Non-Provisional U.S. Patent Application No. 09/912,292, Rosen et al., filed July 26, 2001, NOT PUBLISHED: Pages 1-75 (pages 1 + 2 partially redacted); portion of Table 2; and SEQ ID Nos.: 1762, 73132, and 46156.
	AT	<u>13</u>					Pending Non-Provisional U.S. Patent Application No. 09/912,293, Rosen et al., filed July 26, 2001, NOT PUBLISHED: Pages 1-75 (pages 1 + 2 partially redacted); portion of Table 2; and SEQ ID Nos.: 1762, 73132, and 196475.


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Ebner *et al.*

Appl. No. 10/721,336

Filed: November 26, 2003

For: **Connective Tissue Growth  
Factor - 3**

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 1488.0630003/EKS/KRM

**Third Supplemental Information Disclosure Statement  
Under 37 C.F.R. § 1.97(b)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Third Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Second Supplemental Information Disclosure Statement filed herewith in connection with the above-captioned application. Copies of the documents were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/712,142, filed November 15, 2000, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates

should not be construed as an admission that the information was actually published on the date indicated.


Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed within three months of the date of filing. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz  
Agent for Applicants  
Registration No. 36,351

Date: 2/25/04

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



FORM PTO-1449

**THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT**

 ATTY. DOCKET NO.  
1488.0630003/EKS/KRM

 APPLICATION NO.  
10/721,336

 APPLICANT  
Ebner et al.

 FILING DATE  
November 26, 2003

 GROUP  
To Be Assigned

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB1	6,387,657 B1	05/14/2002	Botstein et al.			10/29/1998
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

	AR	<u>14</u>	Brigstock, D.R., "The Connective Tissue Growth Factor/Cysteine-Rich 61/Nephroblastoma Overexpressed (CCN) Family," <i>Endocr. Rev.</i> 20:189-206, The Endocrine Society (April 1999)				
	AS	<u>14</u>	Inadera, H., et al., "WISP-2 as a Novel Estrogen-Responsive Gene in Human Breast Cancer Cells," <i>Biochem. Biophys. Res. Commun.</i> 275:108-114, Academic Press (August 2000)				
	AT	<u>14</u>	Inadera, H., et al., "WISP-2 is a secreted protein and can be a marker of estrogen exposure in MCF-7 cells," <i>Biochem. Biophys. Res. Commun.</i> 294:602-608, Academic Press (June 2002)				

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <u>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.0630003/EKS/KRM	APPLICATION NO. 10/721,336
	APPLICANT Ebner et al.	
	FILING DATE November 26, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>15</u>	Saxena, N., et al., "Differential expression of WISP-1 and WISP-2 genes in normal and transformed human breast cell lines," <i>Mol. Cell. Biochem.</i> 228:99-104, Kluwer Academic Publishers (December 2001)
	AS	<u>15</u>	Zoubine, M.N., et al., "WISP-2: A Serum-Inducible Gene Differentially Expressed in Human Normal Breast Epithelial Cells and in MCF-7 Breast Tumor Cells," <i>Biochem. Biophys. Res. Commun.</i> 282:421-425, Academic Press (March 2001)
	AT		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Ebner *et al.*

Appl. No. 10/721,336

Filed: November 26, 2003

For: **Connective Tissue Growth  
Factor - 3**

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 1488.0630003/EKS/KRM

**Fourth Supplemental Information Disclosure Statement  
Under 37 C.F.R. § 1.97(b)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Third Supplemental Information Disclosure Statement filed herewith in connection with the above-captioned application. Copies of the documents were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/712,142, filed November 15, 2000, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates

should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed within three months of the date of filing. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz  
Agent for Applicants  
Registration No. 36,351

Date: 2/25/09

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



FORM PTO-1449

FOURTH SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1488.0630003/EKS/KRM

APPLICATION NO.  
10/721,336

APPLICANT  
Ebner et al.

FILING DATE  
November 26, 2003

GROUP  
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM2	WO 93/00430 A1	01/07/1993	WIPO			Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR						
	AS						
	AT	15		Alberts, B., et al., eds., in: <i>Molecular Biology of the Cell</i> , Garland Publishing Co., New York, NY, pp. 1181 and 1187 (1994)			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.0630003/EKS/KRM	APPLICATION NO. 10/721,336
	APPLICANT Ebner et al.	
	FILING DATE November 26, 2003	GROUP To Be Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>16</u>	Benjamini, E. and Leskowitz, S., eds., "Antigenicity," in: <i>Immunology, A Short Course</i> , Wiley-Liss, New York, NY, pp. 40 (1991)
	AS	<u>16</u>	Ngo, T., et al., "Computational Complexity Protein Structure Prediction, and the Levinthal Paradox," in: <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, K. Jr. and Le Grand, S., eds., Springer Verlag, Boston, MA pp. 433 and 492-495 (1994)
	AT	<u>16</u>	Sambrook, J., et al., eds., "Analysis and Cloning of Eukaryotic Genomic DNA," in: <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 9.50 (1989)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449  FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.0630003/EKS/KRM	APPLICATION NO. 10/721,336
	APPLICANT Ebner et al.	
	FILING DATE November 26, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>17</u>	Zhang, R., et al., "Identification of rCop-1, a New Member of the CCN Protein Family, as a Negative Regulator for Cell Transformation," <i>Molec. Cell. Biol.</i> 18:6131-6141, American Society for Microbiology (October 1998)
	AS		
	AT		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.